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ABSTRACT
Hemangiopericytoma is a malignant vascular tumor that is rarely seen in the nasal cavity and paranasal sinuses.
Biological behavior of the tumor is not completely known and its natural history is not predictable. According to
the existing literature, local recurrence rate is not common and distant metastasis is exceedingly rare and majority
of patients have a favorable clinical course. We have presented female Persian case of sinonasal
hemangiopericytoma in which recurrence of the tumor happened very rapidly after initial removal. It also recurred
within two months after reoperation. We have discussed about the characteristics of these tumors and known
prognostic factors. We have finally proposed that the sinonasal hemangiopericytoma may have significantly more
aggressive clinical course than the previous assumption.
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INTRODUCTION
Hemangiopericytoma (HPC) is a rare vascular
tumor derived from Zimmerman’s pericytes,
which surround all capillaries. It accounts for
1% of all vascular tumors (1). It is most
commonly presented in retroperitoneal space,
pelvis and lower extremities and has a
malignant behavior (1).
Of all hemangiopericytomas, about 7.5% are
found in the head and neck with a significant
tendency to occur in nasal cavity and paranasal
sinuses (1, 2). Ethmoid and sphenoid sinuses
are most commonly involved. According to the
majority ofreports, sinonasal HPC has more
benign behaviour and does not have the similar
risk of malignancy and metastasis as HPCs
elsewhere (1). It seems to be due to a variation
in histological and clinical features of
sinonasal type hemangiopericytomas compared
with its other soft tissue counterparts.
Effective treatment requires wide surgical
excision with clear resection margins. These
tumors are relatively radioresistant (3).
CASE REPORT
A 40 year old Persian woman presented to the
otolaryngology clinic of Loghman Hakim general
hospital with a 6 months complains of nasal
obstruction. She had occasional episodes of
epistaxis and headache. There was no significant
past medical and familial history. On physical
examination, there was a fleshy polypoid mass
filling the entire left nasal cavity and displacing
the septum to the right. There was slight bleeding
on touch. A paranasal sinus CT scan was
performed which revealed a soft tissue density
lesion occupying the entire left nasal cavity as
well as maxillary and ethmoid sinuses, projecting
through the posterior choanae into the
nasopharynx and deviating the septum to the
right. In gadolinium enhanced MRI, the tumor did
not seemed to be extended beyond the cribriform
plate. Histopathological examination of the tumor
biopsy specimen revealed tumoral cells, which
were arranged in interlacing fascicles, separated
by dilated and irregularly shaped branching blood
vessels. Cells had oval vesicular and elongated
hyperchromatic nuclei with indistinct cytoplasmic
borders. Mitosis was 5/10 in high power field
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(HPF). Immunohistochemistry (IHC) markers
investigated for confirmation of the diagnosis.
Smooth muscle actin (SMA) was strongly positive
and vimentin was positive while CD34, S100 and
CD99 were negative. Diagnosis of
Hemangiopericytoma was confirmed.
Figure 1.Initial CT scan of the patient.
A grossly complete removal of the tumor was
performed using midface degloving approach. A
complete sphenoethomidectomy along with
maxillectomy and resection of orbital floor was
done. In histopathology report, surgical margins
were free of tumor. Seven weeks after surgery,
the patient developed nasal obstruction again.
The imaging study showed a huge recurrence in
which the tumor had extended from palate up to
cribriform plate with involvement of the hard
plate. The intracranial structures seemed to be
spared. Reoperation performed with the same
approach. The second and third molar teeth and
posterior part of the hard palate were involved by
the tumor. A complete removal including the
resection of hemipalate was done. The
histopathology of the tumor did not show any
difference comparing with the initial one regarding
the pleomorphism of the tumoral cells.
Figure 2. Recurrence of the tumor.
The resected margins were reported to be free of
tumor. Six weeks after the second surgery, the
patient developed proptosis and further
investigations showed a significant recurrence.
The patient refused more work up and preferred
to continue her treatment by non-surgical means.
Hemangiopericytoma is a rare vascular tumor that
may present anywhere in the body. It more
commonly involves the soft tissues of the trunk
and lower extremities. Approximately 17% of all
hemangiopericytomas occurs in the head and neck
region, mainly in the nose and paranasal sinuses
(5). Hemangiopericytoma is present in all ages but
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they are more common in the third to fifth
decades of life. The tumor has no known risk
factors such as sex, race or hereditary. The
pathogenesis of the tumors is not well known.
Sinonasal HPC is commonly presented with nasal
blockage and/or epistaxis. In advanced stages,
HPC presents with local pain, headache and visual
disturbances (6).
Diagnosis is depended on endoscopic examination
and imaging modalities including CT scan and
MRI. The characteristic findingis a soft tissue
mass, which enhances after administration of
intravenous contrast. The role of routine
angiography in the management of the tumor is
not clearly defined. However it is accepted for
pre-operative planning and embolization, which in
turn significantly reduces the risk of
intraoperative hemorrhage (7, 8). The
confirmation of diagnosis is based on
histopathological findings, which reveals the
tumor as tightly packed proliferated spindle cells
surrounded by an intact reticulin sheaths. The
cells have oval to elongated nuclei. The
cytoplasms are sparse, and the nuclei are
vesicular. The arrangement of tumor cells
produces interlacing bundles with many vessels
lining between them occasionally interconnected
with stag horn pattern (6, 8, and 9). In IHC, the
HPC cells are invariably positive for vimentin and
SMA. They are very rarely positive for other
smooth muscle markers such as desmin. A sub-
population of HPC cells are immunoreactive for
factor XIIIa and histocompatibility antigen HLA-
DR. (3, 5).
The treatment of choice is wide surgical resection,
which is the only curative modality. Radiotherapy
has not been considered as a useful modality
because these tumors are radioresistant and there
is no confirmed evidence that chemotherapy is
beneficial for HPC (6, 10). The recurrence rate of
HPC is quite varied, ranging from 7% to 20% (1,
3 and 11).The average time of recurrence is
reported to be 6– 7 years (4). While a primary
incomplete excision has been identified as the
initial factor in recurrent disease, severe nuclear
pleomorphism, osseous invasion, tumor size
larger than 5 cm and a high mitotic rate
significantly increase the risk of recurrence (5). A
metastatic chance of up to 15% has been reported
(1).
We presented a 40 year old female with a large
sinonasal HPC measuring more than 5 cm. It also
involved several adjacent bony elements.
Moreover, these are factors that contribute
with higher recurrence rate; Our patient
demonstrated a clinical course that was
considerably worse than any scenarios which
we could predict using published literature.
The histopathological survey of this tumor did
not show any predictors of invasive tumoral
behavior and the diagnosis of HPC was
confirmed by strong immunohistochemical
evidence. In either the first and second
surgeries, there was no gross residual tumor
remained. The surgical approach with a similar
technique was performed previously on several
similar patients and it resulted in a favorable
outcome (11).  There is no distinct explanation
for the invasive behavior of HPC in the
presented case other than large initial size.
Nonetheless, as we know, there is no reported
case of sinonasal HPC which is as aggressive
as the one we were involved with. Even in the
case of a residual tumor, based on the
published literature, we did not expect a
significant regrowth within few weeks. It
seems that there are some factors other than
the mentioned ones for predicting the course of
this disease. We believe that we should expect
a significantly more malignant behavior on
this previously assumed low grade- slow
growing tumor. This is especially important
when we talk to patients and their families
about the natural course and prognosis of this
tumor. Further works are required to find out
and explain exact predictors of the tumor
behavior and the best treatment modality.
CONCLUSION
The sinonasal hemangiopericytoma may have
significantly more aggressive clinical course than
the previous assumption. The best clinical
predictors of recurrence and treatment modalities
are needed to be found by further works.
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